A blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3) was tested for efficacy in a primate model. Aotus nancymai monkeys were vaccinated with yeast-expressed MSP3 before a lethal challenge with Plasmodium falciparum parasites. Five of 7 control monkeys had acute infections and required treatment to control parasitemia. Only 1 of 7 monkeys vaccinated with MSP3 required this treatment. The efficacy of the MSP3 vaccination appeared to be comparable to that of MSP1 42 , a leading asexual vaccine candidate, in response to which 2 monkeys experienced acute infections. In the MSP3-vaccinated group, protection correlated with prechallenge titers of antibody to MSP3. In the MSP1 and control groups, protection correlated with antibody to MSP3 raised by challenge infection.
Malaria remains one of the world's most burdensome infectious diseases, with mortality and morbidity at near-record levels. All pathology associated with malaria occurs as the parasite undergoes rounds of asexual multiplication in the host's blood. The goal of malaria blood-stage vaccines is to reduce disease severity [1] . Proteins associated with the surface of merozoites (the red blood cell-invasive form of the parasite) are targets for such a vaccine, because they may induce antibodies that interrupt the parasite's life cycle [2] . We report here an attempt to develop a blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3).
MSP3 is a molecule of unknown function associated with the merozoite surface [3, 4] . Uncharacteristically for malarial merozoite surface antigens, this association is not mediated by a transmembrane domain or by an attachment signal for a glycophosphatidylinositol lipid anchor. Structurally related molecules have been identified in Plasmodium vivax [5, 6] , Plasmodium knowlesi [7, 8] , Plasmodium reichenowi [9] , and Plasmodium cynomolgi [6] . In the cases of both Plasmodium falciparum and Plasmodium vivax, MSP3 may be a member of a family of structurally related proteins [6, 10] . Besides the lack of obvious anchoring mechanisms, the unifying structural characteristics of these antigens are homology at the N and C terminals and, sometimes, large stretches of alanine-rich sequences characteristic of coiled-coil domains [6, 11] .
Because MSP3 is expressed on the merozoite surface when the parasite is temporarily exposed to the host immune system, it is a potentially important vaccine candidate. Furthermore, antibodies from humans naturally infected with Plasmodium falciparum, when affinity-purified on MSP3 peptides and antibodies from mice vaccinated with those MSP3 peptides, promote the monocyte-dependent killing of parasites in an in vitro assay [3] . These peptides are derived from a region of MSP3 of high amino acid complexity, possibly indicative of a globular domain separate from some of the molecules' more structurally defined domains (see figure 1 ). We report here on the expression of full-length MSP3 in a heterologous expression system and its efficacy in a nonhuman primate malaria challenge model.
Materials and Methods

Constructs and Protein Expression
Saccharomyces cerevisiae system. The gene for MSP3 was obtained by direct polymerase chain reaction from genomic DNA of the Vietnam Oak Knoll (FVO) strain of Plasmodium falciparum, using forward primer 5 0 -ATTGCTAGCAATAATGTTGCTAGTA-AAGAAATTG-3 0 and reverse primer 5 0 -TAAAATGGGCCCATG-ATTTTTAAAATATTTGGATAATTC-3 0 . The amplified gene encoded amino acids Asn21 to His381 and covered the entire MSP3 sequence, excluding the N-terminal signal sequence (GenBank accession no. AY044180). This polymerase chain reaction product was cloned into the yeast episomal plasmid YEpRPEU-3, as described elsewhere [13] . The resulting plasmids were used to transform the S. cerevisiae cell line VK1 (haploid, trp1 d , lys2-801, pep4
2 :ura). After screening for recombinant protein secretion (ScMSP3), a recombinant protein-positive colony was expanded and was used for fermentation.
Pichia pastoris system. An MSP3 gene equivalent to the fulllength FVO MSP3 was synthesized (GenBank accession no. AF440682; Midland Certified Reagent). This gene was cloned into pPIC9K (Invitrogen). pPIC9K containing synthetic MSP3 was linearized with Bgl I and was integrated into the genome of Pichia pastoris cell line GS115 (his4 2 ; PpMSP3) by homologous recombination. After screening for multicopy integration and protein secretion, an appropriate colony was expanded and was used for shaker flask culture.
Protein Purification
Secreted recombinant proteins were purified from the supernatant of fermenter or shaker flask cultures, as described elsewhere [14] . In brief, the supernatant was concentrated and was dialyzed against 2£ PBS and incubated with nickel-nitrilotriacetic acid agarose. After overnight incubation, the resin was collected and was extensively washed. The bound protein was eluted with 0.25 M sodium acetate (pH 4.5) and/or 0.3 M imidazole (pH 8.0). Size exclusion chromatography was then done on a 16/60 Superdex-75 column (Amersham-Pharmacia Biotech). PpMSP3 was further purified by anion exchange chromatography (Q Sepharose; Amersham-Pharmacia Biotech). N-terminal sequencing and electron spray mass spectroscopy (done by the Biological Resources Branch, National Institute of Allergy and Infectious Diseases) confirmed recombinant protein identity.
SDS-PAGE and Western Blotting
SDS-PAGE was done on 4%-20% gradient polyacrylamide gels, using an Xcell apparatus (Invitrogen) under nonreducing conditions. Some gels were stained with Coomassie blue R250. Proteins from unstained gels were transferred onto nitrocellulose filters with a blot module (Invitrogen). The filters were incubated with rabbit or Aotus nancymai monkey antibodies. After exposure of the filter to the corresponding secondary antibody conjugated with alkaline phosphatase (Kirkegaard & Perry Laboratories) and extensive washes, bound antibodies were visualized with Western blue stain (Promega).
Monkey Trial
A. nancymai monkeys were housed at the National Institutes of Health (NIH) Primate Research Facility in compliance with an NIH Animal Care and Use Committee-approved protocol (LPD-8E). Twenty-one monkeys were randomly assigned to groups of 7. Seven monkeys were vaccinated with 100 mg of PpMSP3, 7 with 25 mg of MSP1 42 [14] , and 7 with 100 mg of Pvs25 [15] , a control yeast-secreted antigen. Each monkey was administered 0.125 mL of antigen emulsion in complete Freund's adjuvant at 4 sites, for a total of 0.5 mL, followed by 2 booster vaccinations with the same dose of antigen in a Montanide ISA51 (Seppic) formulation at 3-week intervals. Fifteen days after the third vaccination, the monkeys were challenged by intravenous infusion of 10 5 red blood cells infected with the highly virulent Plasmodium falciparum FVO strain, freshly passaged through a donor monkey. Parasitemia was monitored daily by Giemsa-stained thin films until treatment, or for >28 days. Reticulocytemia and hematocrit were monitored every second day until day 10 after challenge, at which time daily monitoring began. Monkeys were treated when parasitemia reached 5% or when the hematocrit fell below 25%. All monkeys not treated previously were treated on day 28. The Figure 1 . Expression of merozoite surface protein 3 (MSP3). A, Schematic representation. MSP3 has unique structures, including a signal sequence (SS); 3 alanine-rich heptad repeats, characteristic of coiled-coil structure [11] ; a glutamate-rich highly acidic region; and a C-terminal leucine zipper-like motif. In addition, MSP3 contains a 96-aa predicted globular region, identified by high amino acid complexity by use of the SEG program [12] (nos. in parentheses indicate amino acid positions, based on the sequence of the Plasmodium falciparum Vietnam Oak Knoll parasite strain [GenBank accession no. AY044180]). Antibodies raised against peptides from this region promote monocyte-dependent killing of parasites in an in vitro assay [3] . Amino acid range of recombinant MSP3 (rMSP3) is shown by horizontal rule. The synthetic gene uses yeast-preferential codons and has glutamines substituted for 2 asparagines at putative N-linked glycosylation sites (lozenges). B, Purified forms of rMSP3. rMSP3 produced by Saccharomyces cerevisiae (Sc) or by Pichia pastoris (Pp) was separated on SDS-polyacrylamide gel, and gel was stained with Coomassie blue (CBB). Unstained gel was subjected to Western blotting (WB), using rabbit antiserum to peptide of MSP3 [3] . Molecular mass standards (kDa) are shown at left. treatment consisted of mefloquine administered by intubation in a single dose of 25 mg/kg of body mass.
Aotus monkeys that control their parasitemia either self-cure or develop anemia [14, 16] . Thus, the primary end point includes only data up until the first monkey is treated for low hematocrit rather than for parasitemia. On that day, all monkeys were ranked in order of treatment first, then in order of cumulative parasitemia. A nonparametric Wilcoxon rank sum analysis was then done to compare test groups with the control group. Nonlinear Spearman's regression analysis was used to correlate antibody responses with protection from challenge. Nonparametric Wilcoxon rank sum tests were also used to compare discontinuous data between vaccine groups (e.g., days to peak parasitemia, days to treatment, peak parasitemias, and parasitemia at the time of treatment).
ELISA
Serum antibodies to MSP3 were assayed, as described elsewhere [15] . In brief, flat-bottom 96-well ELISA plates were coated with antigen and incubated at 4 C overnight. The plates were blocked with 3% skim milk (Difco) in TBS-T (0.05% Tween 20 in Tris-buffered saline) for 1 h at room temperature. Serially diluted serum in blocking buffer was added to antigen-coated wells in duplicate and was incubated for 2 h at room temperature. After extensive washing with TBS-T, the plates were incubated for 1 h with the second antibody conjugated with alkaline phosphatase. Bound antibodies were visualized by adding the substrate solution ( p-nitrophenyl phosphate; Sigma). The absorbance at 405 nm was read with a microplate reader. Antibody titers were calculated at 0.5 absorbance units.
Parasite Culture
Plasmodium falciparum FVO strain blood-stage parasites were cultured, as described elsewhere [17] , and were maintained under 5% O 2 , 5% N 2 , and 90% CO 2 at 37 C in RPMI 1640 medium supplemented with 50 mg/L hypoxanthine, 9.2 g/L N-tris [hydroxymethyl]-2-aminoethanesulfonic acid, 2 g/L D-glucose, and 2.32 g/L NaHCO 3 .
Results
Protein expression. Initial attempts to express the mature, full-length FVO allele of Plasmodium falciparum MSP3 in S. cerevisiae were successful (ScMSP3), although the yield was very low (0.4 mg/L). This yield was improved 20-fold (to 8.9 mg/L) by switching expression systems to Pichia pastoris (PpMSP3), combined with a synthetic MSP3 gene (yeast-preferential codons and 2 glutamines instead of glycosylated asparagines). Both recombinant protein products contained multiple bands, even after extensive purification, including the use of strong chaotropes or ionic detergents (figure 1). N-terminal analyses on each band revealed that they are all derived from MSP3 (having N-termini starting at aa 1, 15, 18, 20, 54, and 222 in the sequence of AY0444180). These results suggested that both recombinant proteins had complex tertiary structures involving strong intermolecular interactions. This is consistent with the primary sequence of MSP3, which contains motifs characteristic of coiled coils and a leucine zipper-like motif [11] . Although the theoretical masses of both antigens are very similar (PpMSP3, 42.8 kDa; ScMSP3, 42.6 kDa), the electrical mobility of PpMSP3 on SDS-PAGE differs from that of ScMSP3 (figure 1). However, immunization of mice with ScMSP3 and of rabbits with PpMSP3 both induced antibody responses that recognized MSP3 expressed by Plasmodium falciparum (data not shown). Additionally, anti-MSP3 peptide rabbit antibodies [3] (gift from P. Druilhe, Pasteur Institutes, Paris) recognized both recombinant proteins (figure 1).
Protection in monkeys. New World Aotus monkeys have been used as a model for testing asexual blood-stage vaccines [16, 18, 19] because they are fully susceptible to infection with Plasmodium falciparum and develop life-threatening parasitemia and/or anemia. We selected PpMSP3 for the first monkey trial because of its higher yield and purity and because the electrophoretic mobility of the full-length upper band was identical to that of parasite MSP3 (see figure 2B ). Baculovirus-produced MSP1 (bvMSP1 42 ) [14] and yeast-produced Pvs25 [15] , a transmission-blocking vaccine candidate against Plasmodium vivax, were also used as positive and negative controls, respectively. Three groups of 7 monkeys were vaccinated 3 times before challenge with 10 5 parasites, 15 days after the third vaccination. Parasitemia was then monitored daily. The course of the infection and the outcome for each monkey are shown in table 1 and figure 3 . Five of 7 monkeys vaccinated with Pvs25 had a fulminant infection, fatal without treatment. The remaining 2 eventually required treatment for anemia. Even these 2 control animals, with partially controlled parasitemias, had, at treatment, parasitemias higher than both the peak parasitemias and the parasitemias at treatment of 6 of the 7 animals vaccinated with MSP3 (table 1). As reported elsewhere [14, 20] , vaccination with MSP1 42 confers protection on Aotus monkeys. Five of 7 monkeys vaccinated with bvMSP1 42 were protected against the challenge, with only 2 monkeys requiring treatment for parasitemia. Four of the monkeys with controlled parasitemia later required treatment for anemia. Vaccination with MSP3 also protected monkeys from challenge infection ( figure 3; table 1 ). Only 1 monkey vaccinated with PpMSP3 failed to control parasitemia and required treatment for parasitemia. The remaining surviving animals later required treatment for anemia. The postchallenge day at which treatment was needed was significantly prolonged (geometric mean^SD of 6 surviving monkeys vaccinated with PpMSP3, 15:9^3:1 days, compared with 11:92 :4 days for 7 monkeys vaccinated with Pvs25; P , :05, MannWhitney U test), and the mean postchallenge day of peak parasitemia was significantly decreased (0:7^3:7 days, compared with 6:2^3:7 days; P , :01, Mann-Whitney U test). As judged by the trial's primary statistical outcome, MSP3 vaccination had a statistically significant efficacy, compared with the con-
trol Pvs25 vaccination (P ¼ :05, Wilcoxon rank sum test on cumulative parasitemias at day 14 after challenge). MSP3 vaccination also appeared to perform more effectively than MSP1 42 vaccination but did not reach statistical significance (P ¼ :1).
Serologic analysis. Vaccination with either PpMSP3 or MSP1 42 induced antibodies to the vaccine, and the responses were boosted by the challenge infection ( figure 2A, c and e ) . Antibody titers to MSP3 in monkeys vaccinated with MSP3 appeared to correlate with protection, unlike anti-MSP1 42 responses in monkeys vaccinated with MSP1 42 (but this correlation did not reach significance). Of interest, postchallenge levels of antibody to MSP3 did correlate with protection in the 2 groups of animals not vaccinated with MSP3 (P , :05, Spearman regression analysis). All 5 protected monkeys vaccinated with MSP1 42 and the 2 vaccinated with Pvs25 that did not require treatment for uncontrolled parasitemia developed antibodies to MSP3. In contrast, after challenge, anti-MSP1 antibody titers did not correlate with protection ( figure 2A, d-f ). To confirm that this correlation was specific for MSP3, we measured antibody responses to AMA1, another malarial protein associated with the merozoite surface. After challenge, anti-AMA1 antibody titers correlated inversely with protection (figure 2A, g and h; P , :01). That is, the development of antibodies to AMA1 was a marker for exposure to the parasite. These results suggest that the mechanism by which these monkeys may protect themselves from an acute infection is correlated with the development of an immune response to MSP3, irrespective of the initial vaccination.
Cross-reactive antibody responses. ELISAs showed that some monkeys vaccinated with MSP3 had prechallenge antibodies reactive to MSP1 42 ( figure 2A, f ) and AMA1 (figure 2A,  i ) , as did some vaccinated with Pvs25H ( figure 2A, d and g ). To exclude the possibility that the 6-histidine purification tag shared by all the recombinant proteins used as vaccines might be inducing cross-reactive antibodies, we tested parasite lysates with Western blotting (figure 2B ). Prechallenge serum from all MSP3-vaccinated monkeys recognized not only recombinant MSP3 but also native MSP3 expressed by parasites. At least 3 bands were detected, the mobility of which on SDS-PAGE was very similar to that of recombinant PpMSP3. Serum from the 3 MSP3-vaccinated monkeys that had cross-reactive antibodies to recombinant MSP1 42 by ELISA (indicated by underlining), in addition to recognizing parasite MSP3, also recognized the same molecules recognized by serum from monkeys vaccinated with MSP1 42 (figure 2B ). Without AMA1-vaccinated animals (or monoclonal antibodies against AMA1), it was not possible to identify positively any reactivity to parasite AMA1 in these assays. Thus, we concluded that the cross-reactive antibodies to MSP1 induced by MSP3 vaccination were due to some similarity between MSP3 and MSP1, rather than to the shared 6-histidine sequence.
By examining the reactivity of the monkey serum to another parasite strain and to reduced immunoblots, we found that this cross-reactive response to MSP1 in MSP3-vaccinated monkeys was directed toward the C-terminal 19-kDa region of MSP1. MSP1 exists in 2 allelic forms, typified by the sequences of the FVO and 3D7 parasite strains [21] . The C-terminal 19-kDa portion of MSP1 (MSP1 19 ) is, however, not part of this dimorphism. When immunoblotted against antigen extracts from both the FVO and 3D7 parasite strains, the cross-reactive monkey antiserum recognized MSP1 19 from the 3D7 strain (figure 4), implicating MSP1 19 to be the target of the cross-reactivity. When reduced, the antiserum recognized only parasite MSP3 in both parasite strains, consistent with the highly conformational nature of MSP1 19 (structurally, it is 2 epidermal growth factor-like domains, highly disulfide bonded).
Discussion
We have demonstrated here that MSP3 is a strong candidate for a vaccine against asexual blood-stage parasites of Plasmodium falciparum. This is, to our knowledge, the first report that whole recombinant MSP3 was successfully expressed and that vaccination with MSP3 can protect monkeys from a challenge infection.
The 2 versions of recombinant MSP3 expressed in yeast contained multiple fragments cleaved by yeast proteases, an effect often found in yeast-produced recombinant protein [14] . PpMSP3 has an amino acid sequence identical to that of ScMSP3, except for 2 glutamine!asparagine mutations to avoid any N-linked glycosylation; however, its electrical mobility is far from identical to that of ScMSP3, which suggests major conformational differences. Native MSP3 also has various fragments due to proteolytic processing [23] , migrates as recombinant PpMSP3 does in SDS-PAGE, and, reportedly, lacks any N-glycosylation [24] . The mobility of the full-length PpMSP3 (and several processed fragments) was identical to that of parasite MSP3. Vaccination with PpMSP3 induced antibody responses in Aotus monkeys. Prechallenge antibody titers to MSP3 appeared to correlate (but not significantly) with protective ability, suggesting that antibodies to MSP3 were involved in protection from challenge infection. One possible mechanism of action demonstrated both in vitro and in vivo is antibody-dependent cellular inhibition [3, 25] . Alternatively, antibodies may directly inhibit merozoite invasion of red blood cells, because it has been reported that antibodies to Pk140/143 (the MSP3 homologue of the simian parasite Plasmodium knowlesi ) inhibit merozoite invasion of Rhesus red blood cells [26, 27] . Our preliminary observation is that rabbit anti-MSP3 antibodies do not alter parasite growth in in vitro inhibition assays (authors' unpublished data), which suggests that antibodies themselves are insufficient to suppress parasite growth. Additionally, unlike our observations in the Plasmodium knowlesi study, we did not observe any breakthrough parasites with altered gene sequences in the vaccinated monkeys [27] . However, in a murine model system, disruption of the gene encoding FcgR, a molecule crucial to antibody-dependent cellular inhibition, did not influence resistance of mice to a lethal challenge with Plasmodium yoelii, although the vaccine antigen used was MSP1, not the MSP3 for which the antibody-dependent cellular inhibition mechanism has been proposed [28, 29] , and mechanisms of resistance to Plasmodium yoelii malaria in murine models may differ from those to Plasmodium falciparum malaria in humans and in primate models. Thus, further investigations will be required to define antibody-dependent cellular inhibition as the major mechanism of protective immunity.
One of the other contributions that MSP3 vaccination may make is to generate antibodies also reactive to MSP1. The region in MSP1 that is responsible for the cross-reactivity was localized to the 19-kDa C-terminal portion of MSP1 ( figure 4A ). This was confirmed by the recognition by the anti-MSP3 serum of MSP1 from the 3D7 parasite clone as well as from the FVO clone (figure 4B ), because 3D7 and FVO have different allelic amino acid sequences outside the C-terminal 19-kDa (MSP1 19 ) regions. In addition, reduction and carboxymethylation destroyed MSP1 recognition (but not MSP3 recognition), as might be expected, given the tight disulfide bond-constrained structure of MSP1 19 . Because there is no significant similarity in amino acid sequence between MSP3 and MSP1 42 , the cross-reactivity is probably dependent on similarities in tertiary structure. Such similarities may exist, because the C-terminal portion of the newly described molecule MSP6 [10] is highly homologous to the C-terminal of MSP3, and MSP6 does form a complex with MSP1. Indeed, vaccination of rodents with malarial proteins in earlier studies [30] [31] [32] induced cross-reactive antibodies to other malarial molecules in the presence or absence of similarity in primary structures. However, the development of anti-MSP3 antibodies alone was sufficient to protect monkeys 2778 and T1144 from challenge infection.
Among monkeys vaccinated with either MSP3 or MSP1 42 , a significant level of anemia was observed in monkeys with otherwise controlled parasitemias. This anemia is characteristic of the Aotus monkeys observed previously by us and by others in studies targeting MSPs as vaccine candidates [14, 16, 33, 34] . It is also observed when, rather than by vaccination, monkeys are given immunity by repeated rounds of homologous infection and cure [35] . Current hypotheses to explain this phenomenon invoke various mechanisms of diserythropoeisis and the destruction of large quantities of uninfected red blood cells [35] , which can be supported by mathematical models (authors' unpublished data). It is, however, unclear whether this is a specific phenomenon of the Aotus/Plasmodium falciparum model system or is more generally reflective of the nature of the protective mechanisms elicited by vaccination with MSPs. The answer to this question will be obtained only when these antigens are taken to the field in well-monitored vaccine trials for efficacy.
Besides the protection induced by MSP3 vaccination, one of our most striking findings was the correlation between protection and the development, after challenge, of anti-MSP3 antibodies in non-MSP3-vaccinated monkeys. In contrast, the development of antibodies to AMA1, another MSP, was associated with exposure, not protection. This is consistent with a recent report describing naturally infected human populations, in whom protection from malaria was shown to correlate strongly with the presence of antibodies to a central peptide from the globular domain of MSP3 [36] . This is not necessarily a causal relationship but would seem to be excellent prima facie evidence that priming the immune system with MSP3 may be a very successful vaccination strategy.
